Literature DB >> 26116870

Circulating endothelial cell number and markers of endothelial dysfunction in previously preeclamptic women.

Zeyneb Baspehlivan Tuzcu1, Ebru Asicioglu1, Murat Sunbul2, Beste Ozben2, Hakki Arikan1, Mehmet Koc3.   

Abstract

OBJECTIVE: Patients with preeclampsia (PE) have endothelial dysfunction and an increased future risk of cardiovascular (CV) mortality. The number of circulating endothelial cells (CECs) is markedly increased in conditions associated with a high degree of endothelial cell activation/injury including PE. We hypothesized that the number of CECs continues to be increased in women with a history of PE, reflecting ongoing endothelial cell activation/injury. STUDY
DESIGN: CECs, flow-mediated vasodilation, levels of adhesion molecules and soluble vascular endothelial growth factor receptor-1 (sVEGFR1), and urine albumin/creatinine ratio were determined in 21 healthy women with ongoing normal pregnancy, 24 healthy currently nonpregnant women with a history of normal pregnancy, a total of 17 women with currently active mild (n = 11) or severe (n = 6) PE without hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome, and 16 currently nonpregnant women with a history of mild (n = 10) or severe (n = 6) PE.
RESULTS: Blood samples from women with active preeclampsia had higher CECs (9.9 ± 7.9 cells/mL) than healthy pregnant women (3.0 ± 4.1 cells/mL; P < .001), healthy nonpregnant women with a history of normal pregnancy (3.4 ± 4.0 cells/mL; P < .001), or women with a history of preeclampsia (2.4 ± 2.0 cells/mL; P < .001). The number of CECs were similar between women with a history of preeclampsia and healthy nonpregnant women with a history of normal pregnancy. Patients with active preeclampsia had significantly higher soluble vascular cell adhesion molecule-1, soluble E-selectin, sVEGFR1, and urinary albumin/creatinine ratio than healthy pregnant women. However, soluble vascular cell adhesion molecule-1, soluble E-selectin, urinary albumin/creatinine ratio were similar in women with a history of preeclampsia and healthy nonpregnant women with a history of normal pregnancy. However, women with a history of preeclampsia had higher sVEGFR1 levels than women with a history of normal pregnancy (P < .05).
CONCLUSION: Markers of endothelial activation, dysfunction, and damage were increased in patients with PE. After the delivery, this activation status is similar to the age-matched nonpregnant women with a history of normal pregnancy. However, sVEGFR-1 levels remain higher in women with a history of preeclampsia compared with women without a history of preeclampsia.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  circulating endothelial cells; endothelial dysfunction; preeclampsia; pregnancy; vascular endothelial growth factor receptor-1

Mesh:

Substances:

Year:  2015        PMID: 26116870     DOI: 10.1016/j.ajog.2015.06.043

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  10 in total

1.  The NOX2-derived reactive oxygen species damaged endothelial nitric oxide system via suppressed BKCa/SKCa in preeclampsia.

Authors:  Jie Chen; Qinqin Gao; Lin Jiang; Xueqin Feng; Xiaolin Zhu; Xiaorong Fan; Caiping Mao; Zhice Xu
Journal:  Hypertens Res       Date:  2017-01-12       Impact factor: 3.872

Review 2.  Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia.

Authors:  Juanjuan Chen; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-22       Impact factor: 3.622

3.  Angiogenic imbalance and diminished matrix metalloproteinase-2 and -9 underlie regional decreases in uteroplacental vascularization and feto-placental growth in hypertensive pregnancy.

Authors:  Carlos A Dias-Junior; Juanjuan Chen; Ning Cui; Charles L Chiang; Minglin Zhu; Zongli Ren; Jose S Possomato-Vieira; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2017-09-11       Impact factor: 5.858

4.  Protective Low-Frequency Variants for Preeclampsia in the Fms Related Tyrosine Kinase 1 Gene in the Finnish Population.

Authors:  A Inkeri Lokki; Emma Daly; Michael Triebwasser; Mitja I Kurki; Elisha D O Roberson; Paavo Häppölä; Kirsi Auro; Markus Perola; Seppo Heinonen; Eero Kajantie; Juha Kere; Katja Kivinen; Anneli Pouta; Jane E Salmon; Seppo Meri; Mark Daly; John P Atkinson; Hannele Laivuori
Journal:  Hypertension       Date:  2017-06-26       Impact factor: 10.190

5.  Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia - a longitudinal study.

Authors:  Roberto Romero; Piya Chaemsaithong; Adi L Tarca; Steven J Korzeniewski; Eli Maymon; Percy Pacora; Bogdan Panaitescu; Noppadol Chaiyasit; Zhong Dong; Offer Erez; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  J Matern Fetal Neonatal Med       Date:  2017-03-01

6.  Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia.

Authors:  J S Possomato-Vieira; R A Khalil
Journal:  Adv Pharmacol       Date:  2016-06-14

7.  Restoring placental growth factor-soluble fms-like tyrosine kinase-1 balance reverses vascular hyper-reactivity and hypertension in pregnancy.

Authors:  Minglin Zhu; Zongli Ren; José S Possomato-Vieira; Raouf A Khalil
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-06-08       Impact factor: 3.619

8.  Molecular determinants of microvascular dysfunction in hypertensive pregnancy and preeclampsia.

Authors:  Wentao Yu; Wei Gao; Dan Rong; Zhixian Wu; Raouf A Khalil
Journal:  Microcirculation       Date:  2018-10-19       Impact factor: 2.628

9.  Preeclampsia Increases the Incidence of Postpartum Cerebrovascular Disease in Korean Population.

Authors:  Yejin Park; Geum Joon Cho; Log Young Kim; Tae Seon Lee; Min Jeong Oh; Young Han Kim
Journal:  J Korean Med Sci       Date:  2018-02-05       Impact factor: 2.153

10.  Elevated Levels of Soluble Axl (sAxl) Regulates Key Angiogenic Molecules to Induce Placental Endothelial Dysfunction and a Preeclampsia-Like Phenotype.

Authors:  Shunping Gui; Shengping Zhou; Min Liu; Yanping Zhang; Linbo Gao; Tao Wang; Rong Zhou
Journal:  Front Physiol       Date:  2021-07-13       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.